

FRIULCHEM OBTAINS AUTHORISATION FOR PATENT EXTENSION IN FRANCE
RELATED TO FC-CUBES CHEWABLE TABLETS

THE AUTHORISATION IS PREPARATORY TO EXTENSION IN OTHER EUROPEAN
AND NON-EUROPEAN COUNTRIES AS WELL

Milan, July 6, 2020 - Friulchem S.p.A. (AIM: FCM), innovative SME and one of Italy's leading international players in the third-party research, development and manufacturing (CDMO) of semi-finished and finished products containing active pharmaceutical ingredients and food supplements, specialized predominantly in drug delivery systems for the veterinary sector, is pleased to announce that it has obtained authorization of a new patent application in France for chewable tablets, soon to be extended to other EU and non-EU countries.

The patent is an extension of the FC-Cubes technology and is dedicated to probiotics useful to ensure the normal well-being of the gut and the microbial balance of animals. Live bacteria, more fragile and unstable, have been added to the original matrix, requiring greater protection. The formulation proposed by Friulchem has shown that it reflects all those criteria necessary for their preservation, confirming the company's continued commitment to the research and development of solutions that meet the needs of the market.

"Friulchem is constantly working through intensive R&D to deliver increasingly high-performance, cutting edge technologies. Thanks to continuous research and investment, we have developed an effective and innovative solution that will further help veterinary professionals in the administration of products for large and small animals. The authorization was secured last June and will last twenty years from the date it was obtained," comments Friulchem CEO Disma Giovanni Mazzola.

The press release is available on the website: <https://friulchem.com/it/media-relations/>

Friulchem (AIM:FCM), active in this sector for over 20 years, is today one of Italy's leading CDMOs (*Contract Development Manufacturing Organisations*) operating internationally in the *healthcare* sector through third party research, development and production of intermediate and finished products containing both active pharmaceutical ingredients and food supplements, with particular specialization in *drug delivery* systems for the veterinary sector, which represents Friulchem's excellence, as well as in the development of dossiers for generic medicines for human use. Friulchem is an innovative B2B SME that prides itself on its focus on the end customer. With manufacturing facilities in Vivaro (Pordenone) and administrative headquarters in Milan, it has strong Italian roots. The company, strongly oriented towards R&D activities, boasts established relationships with the leading multinationals in the pharmaceutical sector.

Common Shares ISIN: IT0005378457 - Friulchem Warrant ISIN: 2019-2022 IT0005378366

Friulchem S.p.A.

ir@friulchem.com Tel: +39 02 36591450

Integrae SIM S.p.A. - Nominated Advisor

Giulia Mucciariello

info@Megraesim.it

Tel: +39 02 87208720

CDR Communication - Investor and Media Relations

Silvia Di Rosa silvia.dirosa@cdr-communication.it

Marianna Tremolada marianna.tremolada@cdr-communication.it